Expression of Recombinant Coagulation Factor IX in Human Amniotic Membrane-derived Mesenchymal Stem Cells: A New Strategy to Gene Therapy of Hemophilia B
Journal Title: Iranian Journal of Blood and Cancer - Year 2014, Vol 6, Issue 3
Abstract
Background: Hemophilia B is an X-linked hereditary disorder of blood coagulation system which is caused by factor IX (FIX) deficiency. Factor IX is a plasma glycoprotein that participates in the coagulation process leading to the generation of fibrin. Replacement of factor IX with plasma-derived or recombinant factor IX is the conventional treatment for hemophilia B to raise the factor IX level to therapeutic range. Recently, gene therapy has been regarded as a promising approach to treat hemophilia B. This study was aimed to express the factor IX in human amniotic membrane-derived mesenchymal stem cells (hAM-MSCs). Materials and Methods: Human amniotic membrane-derived mesenchymal stem cells were isolated and characterized from amnion membrane. Factor IX from commercially available plasmid was sub-cloned into pcDNA3.1 vector. Recombinant pcDNA3.1-FIX construct was confirmed by PCR, enzymatic digestion and DNA sequencing. Mesenchymal stem cells were transfected with the recombinant vector. Expression of factor IX was determined by RT-PCR, ELISA and its biological activity assay was performed using aPTT. Results: Isolated hAM-MSCs expressed specific mesenchymal stem cells markers and were able to differentiate to osteocytes and adipocytes lineages. hAM-MSCs expressed hrFIX at mRNA and protein level. The maximum amount of hrFIX was 120 ng/ml at 72 hrs after hAM-MSCs transfection. This hrFIX was biologically active (11% activity), formed fibrin clot in aPTT test and caused more than two fold decrease in clotting time. Conclusion: The hAM-MSCs expressing factor IX would be useful for gene therapy of hemophilia B. However further studies are required to prove these finding. Key words: Hemophilia B, amnion membrane, mesenchymal stem cell, factor IX, gene therapy.
Authors and Affiliations
Mostafa Paridar, Naser Amirizadeh, Mahyar Habibi Roudkenar, Fatemeh Amiri, Hassan Abolghasemi, Mohammad Ali Jalili
Keywords
Related Articles
- EP ID EP364644
- DOI -
- Views 87
- Downloads 0
Leukemia Cutis in a Child with Acute Lymphoblastic Leukemia at Diagnosis and Relapse
This article has no abstract.
Askin Tumor Presenting as Superior Vena Cava Syndrome
This article has no abstract.
A Rare Case of Co-Inheritance of Beta Thalassemia Intermedia and Coagulation FVII Deficiency
We present a 34-year-old man with combination of beta thalassemia intermedia and coagulation factor VII deficiency who was presented with pallor and irregular nose bleeding episodes. On physical examination, he had splen...
Range Determination of Antigen Expression in Myeloid, Erythroid and Lymphoid Cell Lineages among Patients with Myelodysplastic Syndrome
Background: Myelodysplastic syndrome is a mixed clonal disorder of bone marrow progenitor cells. Understanding the pattern of the different lineage-specific, immature, and mature markers in myelodysplastic syndrome will...
Features of Bone Sarcomas at MAHAK Children Hospital, Tehran, Iran during 2007-2009
Background: Bone sarcomas are the most common malignancies of bone tissues in children, and are classified into two groups as osteosarcoma and Ewing’s Sarcoma. Treatment and prognosis depend on the subtype and grade of t...